Eli Stock Based Compensation To Revenue from 2010 to 2024
| LLY Stock | USD 813.33 13.53 1.69% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 0.01841807 | Current Value 0.0145 | Quarterly Volatility 0.0054184 |
Check Eli Lilly financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eli Lilly's main balance sheet or income statement drivers, such as Depreciation And Amortization of 941.5 M, Interest Expense of 510.2 M or Total Revenue of 35.8 B, as well as many indicators such as Price To Sales Ratio of 16.21, Dividend Yield of 0.0073 or PTB Ratio of 51.34. Eli financial statements analysis is a perfect complement when working with Eli Lilly Valuation or Volatility modules.
Eli | Stock Based Compensation To Revenue |
Latest Eli Lilly's Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of Eli Lilly and over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. Eli Lilly's Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eli Lilly's overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
Eli Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 0.01 | |
| Geometric Mean | 0.01 | |
| Coefficient Of Variation | 43.48 | |
| Mean Deviation | 0 | |
| Median | 0.01 | |
| Standard Deviation | 0.01 | |
| Sample Variance | 0.000029 | |
| Range | 0.0215 | |
| R-Value | 0.18 | |
| Mean Square Error | 0.000031 | |
| R-Squared | 0.03 | |
| Significance | 0.52 | |
| Slope | 0.0002 | |
| Total Sum of Squares | 0.0004 |
Eli Stock Based Compensation To Revenue History
About Eli Lilly Financial Statements
Eli Lilly investors use historical fundamental indicators, such as Eli Lilly's Stock Based Compensation To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Eli Lilly. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 0.02 | 0.01 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.